Infections occurring between days 0 and 90 in 133 patients with ALL, CLL, and NHL treated with CD19 CAR-T cells in a phase 1/2 study at the Fred Hutchinson Cancer Research Center were reviewed53. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.